Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

OBJECTIVE: Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggestin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bollard, Julien, Miguela, Verónica, Ruiz de Galarreta, Marina, Venkatesh, Anu, Bian, C Billie, Roberto, Mark P, Tovar, Victoria, Sia, Daniela, Molina-Sánchez, Pedro, Nguyen, Christie B, Nakagawa, Shigeki, Llovet, Josep M, Hoshida, Yujin, Lujambio, Amaia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512174/
https://www.ncbi.nlm.nih.gov/pubmed/27849562
http://dx.doi.org/10.1136/gutjnl-2016-312268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512174/
https://www.ncbi.nlm.nih.gov/pubmed/27849562
http://dx.doi.org/10.1136/gutjnl-2016-312268

Ejemplares similares